University of Michigan

Megan Lim

Kojo Elenitoba-Johnson

Mark J Kiel

Delphine Rolland

Thirunavukkarasu Velusamy

Arul M Chinnaiyan

Nallasivam Palanisamy

Anagh Sahasrabuddhe

Venkatesha Basrur

Bryan L Betz

Kevin P Conlon

Nathanael G Bailey

Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).

Recurrent gene fusions in cutaneous CD30-positive lymphoproliferative disorders

A data analysis method and computer system electronically mines published articles from existing medical literature sources to discover associations that may exist between various diseases and various genes and/or gene mutations or other genetic changes. The method and system then organizes, categorizes and prioritizes the discovered associations in accordance with the strength of evidence supporting these associations. The resulting information can then be integrated into the processing of genome sequencing data to more quickly determine what genome sequencing data is of most relevance for clinical decision makings.

Systems and methods for electronically mining genomic data

Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent RNA fusions as diagnostic markers and clinical targets for leukemia.

RNA chimeras in human leukemia and lymphoma

The present invention provides fusion proteins as biomarkers specific for chromosomal translocation-based conditions (e.g., cancer), related methods for detecting fusion protein biomarkers associated with chromosomal translocation-based conditions, related methods for quantifying amount of fusion protein expression, and related methods for diagnosing chromosomal translocation-based conditions through detection of such fusion protein biomarkers. Such fusion protein biomarkers and related methods additionally find use in research settings.

Compositions and methods relating to fusion protein biomarkers

Growing community of inventors

Ann Arbor, MI, United States of America

Megan Lim